Puma Biotechnology, Inc.
corporate_fare Company Profile
Puma Biotechnology, Inc. (NASDAQ:PBYI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for PBYI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-06, rated 8/10. Across its 10 most recent items scored 7 or higher, the top rating is 8/10, with 8 rated 8 or above. Recent SEC coverage for PBYI spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Puma Biotech Beats Q2 Estimates, Retires All Debt, but Loses Key Patent Appeal
- Puma Biotech Raises 2026 Outlook as NERLYNX Demand Drives Q2 Beat
- Puma Biotechnology Beats Q2 Estimates and Lifts Full-Year Outlook on Robust NERLYNX Demand
- Shareholders Reject CEO's Warrant Extension
- Puma Biotechnology Lifts 2026 Outlook, Q1 EPS Beats Estimates Despite Revenue Dip
Financial Snapshot
Short Interest & Short Volume
13.80 days to coverFINRA reported short interest of 4,319,663 shares in PBYI as of the September 15, 2026 settlement, a 1.1% increase from the prior period — about 13.8 days to cover at its recent average daily volume. On October 2, 2026, 69.0% of PBYI volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.